HRYZ Biotech Co.
8 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (NCT06277154) | HRYZ Biotech Co. | 2024-02-21 |
| HRYZ-T101 Injection for HPV18 Positive Solid Tumor (NCT05952947) | HRYZ Biotech Co. | 2023-11-01 |
| MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. (NCT05877651) | HRYZ Biotech Co. | 2020-04-21 |
| MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma (NCT04074564) | HRYZ Biotech Co. | 2019-11-22 |
| A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor (NCT03393416) | HRYZ Biotech Co. | 2018-04-19 |
Track HRYZ Biotech Co. automatically
Every clearance here is in the API, with alerts when new ones post.